Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-10-28
2011-12-06
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S330000, C424S078060
Reexamination Certificate
active
08071555
ABSTRACT:
The disclosed invention provides tetrapeptides with the amino acid sequence proline-glutamine-glutamate-X (P-Q-E-X), where X can be either lysine (K) or isoleucine (I). These tetrapeptides inhibit ultraviolet light (UV)-induced expression of the pro-inflammatory cytokine interleukin-6 (IL-6) by skin epithelial cells and fibroblasts. Furthermore, the tetrapeptides repress the upregulation of matrix metalloproteinase-1 (MMP-1) by skin fibroblasts induced by either direct exposure to UV rays or treatment with media conditioned by UV-treated keratinocytes. The small size and bio-activity of the tetrapeptides render them suitable for use in therapies directed to inflammatory skin disorders and as active ingredients in skin care products.
REFERENCES:
patent: 5464820 (1995-11-01), Burton et al.
patent: 5763576 (1998-06-01), Powers
patent: 5770568 (1998-06-01), Auerswald et al.
patent: 6096327 (2000-08-01), Lezdey et al.
patent: 6143742 (2000-11-01), Fuisz
patent: 6211155 (2001-04-01), Dussourd et al.
patent: 6262021 (2001-07-01), Uvnas-Moberg et al.
patent: 6284802 (2001-09-01), Bissett et al.
patent: 6294181 (2001-09-01), Lezdey
patent: 6319907 (2001-11-01), Ferguson
patent: 6344189 (2002-02-01), Bunn et al.
patent: 6492326 (2002-12-01), Robinson et al.
patent: 6537968 (2003-03-01), Lezdey et al.
patent: 6962904 (2005-11-01), Sandberg et al.
patent: 6967023 (2005-11-01), Eini et al.
patent: 6974799 (2005-12-01), Lintner
patent: 7041506 (2006-05-01), Campbell et al.
patent: 7238656 (2007-07-01), Wormser
patent: 7265097 (2007-09-01), Kydonieus et al.
patent: 7271239 (2007-09-01), Bobek
patent: 2003/0175745 (2003-09-01), Dean et al.
patent: 2004/0009911 (2004-01-01), Harris et al.
patent: 2004/0167072 (2004-08-01), Aggarwal et al.
patent: 2005/0085422 (2005-04-01), Georgiades et al.
patent: 2005/0288229 (2005-12-01), Sindrey et al.
patent: 2006/0046271 (2006-03-01), Hallahan
patent: 2007/0021347 (2007-01-01), Khan et al.
patent: 2007/0077305 (2007-04-01), Le et al.
patent: 2007/0166267 (2007-07-01), Majewski et al.
patent: 2007/0183970 (2007-08-01), Goldenberg et al.
patent: 2007/0224150 (2007-09-01), Chung
patent: 2276542 (2000-12-01), None
patent: 102004050563 (2006-04-01), None
patent: 0858808 (1998-08-01), None
patent: 1004595 (2000-05-01), None
patent: 1 634 576 (2006-03-01), None
patent: 1 815 843 (2007-08-01), None
patent: 1357121 (1974-06-01), None
patent: WO 89/10099 (1989-11-01), None
patent: WO 95/28832 (1995-11-01), None
patent: WO 00/43417 (2000-07-01), None
patent: WO 02/079408 (2002-10-01), None
patent: WO 02/092623 (2002-11-01), None
patent: WO 2006/042625 (2006-04-01), None
patent: WO 2006/053688 (2006-05-01), None
patent: WO 2006/108963 (2006-10-01), None
patent: WO 2007/098255 (2007-08-01), None
patent: WO 2007/098255 (2007-08-01), None
Kassem, 1996, Journal of Bone and Mineral Research, 11, 193-199.
Herberts, 2003, Molecular Immunology, 39, 567-575.
Cecile, 2000, Eur. J. Immunol., 30, 1172-1181.
Schultz et al., Extracellular matrix: review of its roles in acute and chronic wounds,World Wide Wounds(www.worldwidewounds.com) (Aug. 2005).
Katayama et al., A pentapeptide from type I procollagen promotes extracellular matrix production,Journal of Biological Chemistry268:9941-9944 (1993).
Greenbaum et al., Chemical approaches for functionally probing the proteome,Molecular and Cellular Proteomics1:60-68 (2002).
Krstenansky et al., Probing proteinase active sites using oriented peptide mixture libraries—ADAM-10,Letters in Drug Design and Discovery1:6-13 (2004).
Tran et al., Extracellular matrix signaling through growth factor receptors during wound healing,Wound Repair and Regeneration12:262-268 (2004).
Maquart et al., [Regulation of cell activity by the extracellular matrix: the concept of matrikines],Journal de la Société de biologie193:423-428 (1999) Abstract Only.
Duca et al., Elastin as a matrikine,Critical Reviews in Oncology/Hematology49:235-244 (2004).
Arul et al., Biotinylated GHK peptide incorporated collagenous matrix: a novel biomaterial for dermal wound healing in rats,Journal of Biomedical Materials Research Part B: Applied Biomaterials73:383-391 (2005).
Tran et al., Matrikines and matricryptins: implications for cutaneous cancers and skin repair,Journal of Dermatological Science40:11-20 (2005).
Heilborn et al., The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium,Journal of Investigative Dermatology120:379-389 (2003).
Bessalle et al., Structure-function studies of amphiphilic antibacterial peptides,J. Med. Chem.36:1203-1209 (1993).
Oh et al., Design, synthesis and characterization of antimicrobial pseudopeptides corresponding to membrane-active peptide,J. Peptide Res.54:129-136 (1999).
Lee Pha et al. (2004), HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair,Wound Rep. Reg.12:351-358.
Reed Wa et al. (1992), Enhanced in vitro growth of murine fibroblast cells and preimplantation embryos cultured in medium supplemented with an amphipathic peptide,Mol. Rep. Develop.31:106-113.
Andreu D et al. (1985), N-terminal analogues of cecropin A: synthesis, antibacterial activity, and conformational properties,Biochemistry24:1683-1688.
Morgan K et al. (1992), Identification of an immunodominant B-cell epitope in bovine type II collagen and production of antibodies to type II collagen by immunization with a synthetic peptide representing this epitope,Immunology77:609-616.
Degryse B et al. (2005), Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity,J. Biol. Chem.280:24792-24803.
Wu W-J and Raleigh DP (1998), Local control of peptide conformation: stabilization ofcisproline peptide bonds by aromatic proline interactions,Biopolymers45:381-394.
Kessler E and Yaron A (1973), A novel aminopeptidase fromClostridium histolyticum, Biochem. Biophys. Res. Comm.50:405-412.
Wunsch E et al. (1971), Zur spezifitat der kollagenase,Hoppe-Seyler's Zeitschrift Fuer Physiologische Chemie352:1568-1579.
Ye et al. (2002), Distinct molecular mechanism for initiating TRAF6 signalling,Nature418:443-447.
Adhami et al. (2003), Suppression of Ultraviolet B Exposure-Mediated Activation of NF-κB in Normal Human Keratinocytes by Resveratrol,Neoplasia5:74-82.
Tanaka et al. (2005), Prevention of the Ultraviolet B-Mediated Skin Photoaging by a Nuclear Factor κB Inhibitor, Parthenolide,J. Pharmacol. Experimental Therapeutics315:624-630.
Zittermann et al. (2006), Basic Fibroblast Growth Factor (bFGF, FGF-2) Potentiates Leukocyte Recruitment to Inflammation by Enhancing Endothelial Adhesion Molecule Expression,Am. J. Pathol.168 (3):835-846.
Martin et al. (2008), Photoprotective effect of a water-soluble extract ofRosmarinus officinalisL. against UV-induced matrix metalloproteinase-1 in human dermal fibroblasts and reconstructed skin,Eur. J. Dermatol.18(2):128-35.
Fagot et al. (2002), Direct role of human dermal fibroblasts and indirect participation of epidermal keratinocytes in MMP-1 production after UV-B irradiation,Arch. Dermatol. Res.293:576-583.
Wang et al. (2006), UVB-irradiated human keratinocytes and interleukin-1α indirectly increase MP kinase/AP-1 activation and MMP-1 production in UVA-irradiated dermal fibroblasts,Chinese Medical Journal119(10):827-831.
Fagot et al. (2004), Matrix Metalloproteinase-1 Production Observed After Solar-Simulated Radiation Exposure is Assumed by Dermal Fibroblasts but Involves a Paracrine Activation Through Epidermal Keratinocytes,Photochemistry and Photobiology79(6):499-505.
Protein Sequence (online database registry) entitled “L-Isoleucinamide, L-prolyl-L-glutaminyl-L-alpha-glutamyl-,” Sep. 4, 2008.
Falla Timothy J.
Harris Scott M.
Zhang Lijuan
Gudibande Satyanarayana
Helix BioMedix Inc.
Novak Druce & Quigg LLP
Tsang Cecilia J
LandOfFree
Protective skin care peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protective skin care peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protective skin care peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4314042